메뉴 건너뛰기




Volumn 56, Issue 2, 2015, Pages 956-961

Pharmacokinetics of bevacizumab and its effects on serum vegf and igf-1 in infants with retinopathy of prematurity

Author keywords

Bevacizumab; Intraocular injection; Laser; Retinopathy of prematurity; VEGF

Indexed keywords

BEVACIZUMAB; SOMATOMEDIN C; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

EID: 84922570321     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15842     Document Type: Article
Times cited : (128)

References (33)
  • 1
    • 84870859098 scopus 로고    scopus 로고
    • An update on progress and the changing epidemiology of causes of childhood blindness worldwide
    • Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS. 2012;16:501-507.
    • (2012) J AAPOS , vol.16 , pp. 501-507
    • Kong, L.1    Fry, M.2    Al-Samarraie, M.3    Gilbert, C.4    Steinkuller, P.G.5
  • 3
    • 17244381522 scopus 로고    scopus 로고
    • Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial
    • discussion
    • Good WV. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–248; discussion 248–250.
    • (2004) Trans am Ophthalmol Soc , vol.102 , pp. 233-248
    • Good, W.V.1
  • 4
    • 34848909008 scopus 로고    scopus 로고
    • Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity
    • Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245:1727–1730.
    • (2007) Graefes Arch Clin Exp Ophthalmol , vol.245 , pp. 1727-1730
    • Chung, E.J.1    Kim, J.H.2    Ahn, H.S.3    Koh, H.J.4
  • 5
    • 49449116019 scopus 로고    scopus 로고
    • Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study
    • Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez- Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008;126:1161–1163.
    • (2008) Arch Ophthalmol , vol.126 , pp. 1161-1163
    • Kong, L.1    Mintz-Hittner, H.A.2    Penland, R.L.3    Kretzer, F.L.4    Chevez-Barrios, P.5
  • 6
    • 55449105439 scopus 로고    scopus 로고
    • Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study
    • Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450–1455.
    • (2008) Br J Ophthalmol , vol.92 , pp. 1450-1455
    • Kusaka, S.1    Shima, C.2    Wada, K.3
  • 8
    • 79951821800 scopus 로고    scopus 로고
    • Efficacy of intravitreal bevacizumab for stage 3þ retinopathy of prematurity
    • Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3þ retinopathy of prematurity. N Engl J Med. 2011;364:603–615.
    • (2011) N Engl J Med , vol.364 , pp. 603-615
    • Mintz-Hittner, H.A.1    Kennedy, K.A.2    Chuang, A.Z.3
  • 9
    • 84856316155 scopus 로고    scopus 로고
    • Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (APROP)
    • Wutthiworawong B, Thitiratsanont U, Saovaprut C, et al. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (APROP). J Med Assoc Thai. 2011;94(suppl 3):S15–S21.
    • (2011) J Med Assoc Thai , vol.94
    • Wutthiworawong, B.1    Thitiratsanont, U.2    Saovaprut, C.3
  • 10
    • 84872500730 scopus 로고    scopus 로고
    • Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity
    • Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2011;17:17.
    • (2011) Am J Ophthalmol , vol.17
    • Sato, T.1    Wada, K.2    Arahori, H.3
  • 11
    • 0037064010 scopus 로고    scopus 로고
    • Insulin-like growth factor 1 induces hypoxia-inducible factor 1- mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells
    • Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1- mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002; 277:38205–38211.
    • (2002) J Biol Chem , vol.277 , pp. 38205-38211
    • Fukuda, R.1    Hirota, K.2    Fan, F.3    Jung, Y.D.4    Ellis, L.M.5    Semenza, G.L.6
  • 12
    • 78650203216 scopus 로고    scopus 로고
    • Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy
    • Stahl A, Chen J, Sapieha P, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;177:2715–2723.
    • (2010) Am J Pathol , vol.177 , pp. 2715-2723
    • Stahl, A.1    Chen, J.2    Sapieha, P.3
  • 13
    • 84911988207 scopus 로고    scopus 로고
    • Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
    • Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636–1641.
    • (2014) Br J Ophthalmol , vol.98 , pp. 1636-1641
    • Avery, R.L.1    Castellarin, A.A.2    Steinle, N.C.3
  • 14
    • 84922524632 scopus 로고    scopus 로고
    • AVASTIN (bevacizumab) solution for intravenous infusion prescribing information, Accessed March 2014
    • AVASTIN (bevacizumab) solution for intravenous infusion prescribing information. Available at: http://www.gene.com/download/pdf/avastin_prescribing.pdf. Accessed March 2014.
  • 15
    • 33749426139 scopus 로고    scopus 로고
    • The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration
    • Steinbrook R. The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409–1412.
    • (2006) N Engl J Med , vol.355 , pp. 1409-1412
    • Steinbrook, R.1
  • 16
    • 54249138516 scopus 로고    scopus 로고
    • Monoclonal antibody pharmacokinetics and pharmacodynamics
    • Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558.
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 548-558
    • Wang, W.1    Wang, E.Q.2    Balthasar, J.P.3
  • 17
    • 24144455629 scopus 로고    scopus 로고
    • Pharmacokinetics and concentrationeffect relationships of therapeutic monoclonal antibodies and fusion proteins
    • Ternant D, Paintaud G. Pharmacokinetics and concentrationeffect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5(suppl 1):S37-S47.
    • (2005) Expert Opin Biol Ther , vol.5
    • Ternant, D.1    Paintaud, G.2
  • 18
    • 79955022978 scopus 로고    scopus 로고
    • Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications
    • Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51:5403–5420.
    • (2010) Invest Ophthalmol Vis Sci , vol.51 , pp. 5403-5420
    • Edelhauser, H.F.1    Rowe-Rendleman, C.L.2    Robinson, M.R.3
  • 19
    • 0025106266 scopus 로고
    • Permeability of ocular vessels and transport across the blood-retinal-barrier
    • Tornquist P, Alm A, Bill A. Permeability of ocular vessels and transport across the blood-retinal-barrier. Eye (Lond). 1990; 4(pt 2):303–309.
    • (1990) Eye (Lond) , vol.4 , pp. 303-309
    • Tornquist, P.1    Alm, A.2    Bill, A.3
  • 20
    • 0032864292 scopus 로고    scopus 로고
    • Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
    • Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536–544.
    • (1999) Toxicol Pathol , vol.27 , pp. 536-544
    • Mordenti, J.1    Cuthbertson, R.A.2    Ferrara, N.3
  • 21
  • 23
    • 77649253359 scopus 로고    scopus 로고
    • FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye
    • Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis. 2009; 15:2803–2812.
    • (2009) Mol Vis , vol.15 , pp. 2803-2812
    • Kim, H.1    Robinson, S.B.2    Csaky, K.G.3
  • 24
    • 41849086985 scopus 로고    scopus 로고
    • Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye
    • Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. Br J Ophthalmol. 2008;92: 541–544.
    • (2008) Br J Ophthalmol , vol.92 , pp. 541-544
    • Peters, S.1    Heiduschka, P.2    Julien, S.3    Bartz-Schmidt, K.U.4    Schraermeyer, U.5
  • 25
    • 80051490622 scopus 로고    scopus 로고
    • VEGF signalling controls GnRH neuron survival via NRP1 independently of KDR and blood vessels
    • Cariboni A, Davidson K, Dozio E, et al. VEGF signalling controls GnRH neuron survival via NRP1 independently of KDR and blood vessels. Development. 2011;138:3723–3733.
    • (2011) Development , vol.138 , pp. 3723-3733
    • Cariboni, A.1    Davidson, K.2    Dozio, E.3
  • 26
    • 79958044393 scopus 로고    scopus 로고
    • VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm
    • Erskine L, Reijntjes S, Pratt T, et al. VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm. Neuron. 2011;70:951–965.
    • (2011) Neuron , vol.70 , pp. 951-965
    • Erskine, L.1    Reijntjes, S.2    Pratt, T.3
  • 27
    • 84863317107 scopus 로고    scopus 로고
    • Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy
    • Davidovic SP, Nikolic SV, Curic NJ, et al. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Eur J Ophthalmol. 2012;22: 792–798.
    • (2012) Eur J Ophthalmol , vol.22 , pp. 792-798
    • Davidovic, S.P.1    Nikolic, S.V.2    Curic, N.J.3
  • 28
    • 84875213214 scopus 로고    scopus 로고
    • Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema
    • Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454–459.
    • (2013) Br J Ophthalmol , vol.97 , pp. 454-459
    • Zehetner, C.1    Kirchmair, R.2    Huber, S.3    Kralinger, M.T.4    Kieselbach, G.F.5
  • 29
    • 84856539058 scopus 로고    scopus 로고
    • Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab
    • Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90:e25–e30.
    • (2012) Acta Ophthalmol , vol.90 , pp. e25-e30
    • Carneiro, A.M.1    Costa, R.2    Falcao, M.S.3
  • 30
    • 14344279279 scopus 로고    scopus 로고
    • Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity
    • Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98:5804–5808.
    • (2001) Proc Natl Acad Sci U S A , vol.98 , pp. 5804-5808
    • Hellstrom, A.1    Perruzzi, C.2    Ju, M.3
  • 32
    • 0032758384 scopus 로고    scopus 로고
    • Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
    • Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999; 12:1390–1395.
    • (1999) Nat Med , vol.12 , pp. 1390-1395
    • Smith, L.E.1    Shen, W.2    Perruzzi, C.3
  • 33
    • 0025352643 scopus 로고
    • Growth patterns of low birth weight preterm infants: A longitudinal analysis of a large, varied sample
    • Casey PH, Kraemer HC, Bernbaum J, et al. Growth patterns of low birth weight preterm infants: a longitudinal analysis of a large, varied sample. J Pediatr. 1990;117(2 pt 1):298–307.
    • (1990) J Pediatr , vol.117 , Issue.2 , pp. 298-307
    • Casey, P.H.1    Kraemer, H.C.2    Bernbaum, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.